Field Medical Unveils Groundbreaking PFA Trial Results at AF Symposium

Field Medical, Inc. has announced significant advancements in cardiac treatment with the presentation of late-breaking clinical trial data from its pioneering Field PULSE study. This announcement was made during the 31st Annual International AF Symposium 2026, held from February 5 to 7 in Boston. The study showcases the effectiveness of pulsed field ablation (PFA) technologies in treating complex cardiac arrhythmias.

The Field PULSE study evaluates a novel high-voltage, sub-second pulsed field waveform. This technology is delivered through the company’s FieldForce Ablation System and Catheter, which is designed to enable instantaneous ablation via point-by-point energy delivery. This approach eliminates the need for prolonged contact between the catheter and tissue, enhancing the efficiency of the procedure.

Vivek Y. Reddy, M.D., the principal investigator of the Field PULSE study and an electrophysiologist at Mount Sinai in New York, emphasized the benefits of this method: “By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets.” This innovation not only aims to improve procedural efficiency but also maintains the flexibility that physicians require in focal ablation.

Key Findings from the Field PULSE Study

The study reported impressive results regarding the efficacy of the FieldForce Ablation System. Notably, lesions were created in under 200 milliseconds, allowing for rapid point-by-point ablation. The median time for bilateral pulmonary vein isolation (PVI) was recorded at 12.5 minutes, with the fastest procedure completed in just 7.7 minutes.

The durability of the PVI was highlighted as well, showing a progressive improvement with the optimized waveform. Specifically, the PVI durability rates were reported at 94.2% by vein and 84.6% by patient.

In terms of safety, the study found no serious device-related adverse events, acute kidney injuries, or clinically relevant hemolysis. Among the patients evaluated with brain MRI, no silent cerebral lesions were observed, indicating a promising safety profile for this new technology.

These findings mark a significant expansion of Field Medical’s clinical evidence, extending its high-voltage focal PFA approach beyond ventricular arrhythmias to include therapies for atrial fibrillation (AF). The results, in conjunction with previously reported six-month data on ventricular tachycardia, support the potential of a versatile ablation platform for treating various heart chambers efficiently.

Steven Mickelsen, M.D., founder and chief technology officer of Field Medical, remarked on the implications of the results: “The Field PULSE results reinforce our approach of deliberately architecting focal PFA to address the fundamental limitations of existing methods.” He noted the importance of data validation in establishing a reliable treatment option for complex arrhythmias.

Future Directions and Presentations

The Field PULSE data were presented during the Late Breaking Clinical Trials Session I at the AF Symposium 2026. Field Medical is scheduled to appear again on February 6 from 07:30 to 08:30 during a scientific session focusing on the biophysics of PFA for AF. A presentation titled “Maximizing Lesion Depth Using High Voltage PFA Waveform” will be delivered by Kenneth Ellenbogen, M.D.. Additionally, a case transmission session on February 7 will highlight AF ablation using the FieldForce Ablation System.

The FieldForce Ablation System represents a significant innovation in cardiac ablation technology. It is a focal, contact-sensing PFA system built on proprietary FieldBending technology, designed to deliver targeted high-intensity electric fields efficiently. This system aims to serve as a universal ablation platform for both atrial and ventricular applications, enhancing the precision and safety of cardiac treatments.

Founded in 2022, Field Medical is dedicated to advancing PFA solutions for complex cardiac arrhythmias. The company received Breakthrough Device Designation in 2024 and was accepted into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in the journal Circulation, further establishing the company’s commitment to innovation in cardiac care.

For further information, visit www.fieldmedicalinc.com and follow Field Medical on LinkedIn, X, and YouTube.

The FieldForce Ablation System is currently an investigational device, limited by federal law to investigational use.